195 related articles for article (PubMed ID: 31073843)
41. Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients.
Botterel F; Cabaret O; Foulet F; Cordonnier C; Costa JM; Bretagne S
J Clin Microbiol; 2012 Feb; 50(2):227-31. PubMed ID: 22162560
[TBL] [Abstract][Full Text] [Related]
42. Detection of Pneumocystis jirovecii by nested PCR in HIV-negative patients with pulmonary disease.
Santos CR; de Assis ÂM; Luz EA; Lyra L; Toro IF; Seabra JCC; Daldin DH; Marcalto TU; Galasso MT; Macedo RF; Schreiber AZ; Aoki FH
Rev Iberoam Micol; 2017; 34(2):83-88. PubMed ID: 28214275
[TBL] [Abstract][Full Text] [Related]
43. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients.
Fortún J; Martín-Dávila P; Gomez Garcia de la Pedrosa E; Silva JT; Garcia-Rodríguez J; Benito D; Venanzi E; Castaño F; Fernández-Ruiz M; Lazaro F; García-Luján R; Quiles I; Cabanillas JJ; Moreno S; Aguado JM
J Infect; 2016 Jun; 72(6):738-744. PubMed ID: 27025205
[TBL] [Abstract][Full Text] [Related]
44. Does molecular analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of respiratory infections in hemato-oncological patients?
Oren I; Hardak E; Zuckerman T; Geffen Y; Hoffman R; Yigla M; Avivi I
Int J Infect Dis; 2016 Sep; 50():48-53. PubMed ID: 27484225
[TBL] [Abstract][Full Text] [Related]
45. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies.
Luong ML; Filion C; Labbé AC; Roy J; Pépin J; Cadrin-Tourigny J; Carignan S; Sheppard DC; Laverdière M
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):132-9. PubMed ID: 20846585
[TBL] [Abstract][Full Text] [Related]
46. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients.
Buchheidt D; Baust C; Skladny H; Baldus M; Bräuninger S; Hehlmann R
Br J Haematol; 2002 Mar; 116(4):803-11. PubMed ID: 11886384
[TBL] [Abstract][Full Text] [Related]
47. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients.
Nguyen MH; Leather H; Clancy CJ; Cline C; Jantz MA; Kulkarni V; Wheat LJ; Wingard JR
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1043-50. PubMed ID: 21087680
[TBL] [Abstract][Full Text] [Related]
48. Comparison of PCR-ELISA and Real-Time PCR for invasive aspergillosis diagnosis in patients with hematological malignancies.
Hadrich I; Mary C; Makni F; Elloumi M; Dumon H; Ayadi A; Ranque S
Med Mycol; 2011 Jul; 49(5):489-94. PubMed ID: 21108574
[TBL] [Abstract][Full Text] [Related]
49. Quantitative TaqMan PCR for detection of Pneumocystis jiroveci.
Brancart F; Rodriguez-Villalobos H; Fonteyne PA; Peres-Bota D; Liesnard C
J Microbiol Methods; 2005 Jun; 61(3):381-7. PubMed ID: 15767014
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic role of polymerase chain reaction in bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in immunocompromised patients - A retrospective cohort study.
Hardak E; Fuchs E; Leskes H; Geffen Y; Zuckerman T; Oren I
Int J Infect Dis; 2019 Jun; 83():20-25. PubMed ID: 30926540
[TBL] [Abstract][Full Text] [Related]
51. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.
Francesconi A; Kasai M; Petraitiene R; Petraitis V; Kelaher AM; Schaufele R; Hope WW; Shea YR; Bacher J; Walsh TJ
J Clin Microbiol; 2006 Jul; 44(7):2475-80. PubMed ID: 16825367
[TBL] [Abstract][Full Text] [Related]
52. Role of bi-weekly serum galactomannan screening for the diagnosis of invasive aspergillosis in haematological cancer patients.
Couchepin J; Brunel AS; Jaton K; Meylan P; Bochud PY; Lamoth F
Mycoses; 2018 Jun; 61(6):350-354. PubMed ID: 29453853
[TBL] [Abstract][Full Text] [Related]
53. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies.
Bergeron A; Belle A; Sulahian A; Lacroix C; Chevret S; Raffoux E; Arnulf B; Socié G; Ribaud P; Tazi A
Chest; 2010 Feb; 137(2):410-5. PubMed ID: 19801584
[TBL] [Abstract][Full Text] [Related]
54. A highly sensitive novel PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveloar lavage specimens from immunocompromised patients.
Tia T; Putaporntip C; Kosuwin R; Kongpolprom N; Kawkitinarong K; Jongwutiwes S
Clin Microbiol Infect; 2012 Jun; 18(6):598-603. PubMed ID: 21951463
[TBL] [Abstract][Full Text] [Related]
55. Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test.
Eigl S; Prattes J; Reinwald M; Thornton CR; Reischies F; Spiess B; Neumeister P; Zollner-Schwetz I; Raggam RB; Flick H; Buchheidt D; Krause R; Hoenigl M
Int J Antimicrob Agents; 2015 Oct; 46(4):401-5. PubMed ID: 26187363
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan.
de Mol M; de Jongste JC; van Westreenen M; Merkus PJ; de Vries AH; Hop WC; Warris A; Janssens HM
Pediatr Pulmonol; 2013 Aug; 48(8):789-96. PubMed ID: 22949309
[TBL] [Abstract][Full Text] [Related]
57. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients.
Alanio A; Desoubeaux G; Sarfati C; Hamane S; Bergeron A; Azoulay E; Molina JM; Derouin F; Menotti J
Clin Microbiol Infect; 2011 Oct; 17(10):1531-7. PubMed ID: 20946413
[TBL] [Abstract][Full Text] [Related]
58. Bronchoalveolar lavage in immunocompromised patients with haematological malignancy--value of new microbiological methods.
Hohenthal U; Itälä M; Salonen J; Sipilä J; Rantakokko-Jalava K; Meurman O; Nikoskelainen J; Vainionpää R; Kotilainen P
Eur J Haematol; 2005 Mar; 74(3):203-11. PubMed ID: 15693789
[TBL] [Abstract][Full Text] [Related]
59. Ability of quantitative PCR to discriminate
Perret T; Kritikos A; Hauser PM; Guiver M; Coste AT; Jaton K; Lamoth F
J Med Microbiol; 2020 May; 69(5):705-711. PubMed ID: 32369002
[No Abstract] [Full Text] [Related]
60. Utility of bronchoalveolar lavage in the management of immunocompromised patients presenting with lung infiltrates.
Choo R; Naser NSH; Nadkarni NV; Anantham D
BMC Pulm Med; 2019 Feb; 19(1):51. PubMed ID: 30808314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
